Clinical condition

There is no specific antidote for acrolein exposure. Treatment of exposure should be directed at the control of symptoms and the clinical condition. Most of the harmful effects of acrolein result from its highly irritating and corrosive properties. 

The immunorestorative potential of inosiplex has been evaluated in several clinical conditions, including post-surgical trauma, cancer patients with concurrent viral infections, and cancer patients receiving radiotherapy or chemotherapy. For example, most (84%) of the surgery patients remained immunologicaHy depressed, but 56% of the inosiplex-treated surgery patients had complete restoration of normal skin test reactivity (probability level < 0.0005). The use of inosiplex as an adjuvant to chemotherapy or radiotherapy appears to be valuable in the prophylaxis against opportunistic infections. 

The relevance of clinical conditions with chronic low blood pressure or hypotension has been questioned, with the exception of a few rare clinical syndromes. Temporary increases or decreases of blood pressure are often seen in clinical medicine in the context of acute illnesses or interventions. 

Because some patients are more sensitive to side effects with digoxin, the dosage is selected carefully and adjusted as the clinical condition indicates. Adverse reactions were more common and severe in past years before careful attention to weight, renal function, and the concurrent administration of certain medications was given. The incidence and severity of digoxin toxicity has decreased significantly in recent years. 

One woman died after 1 week, with multiorgan failure despite intravenous dimercaptosuccinic acid chelation. The other gradually recovered from severe neuropsychiatric symptoms over several months. She had been chelated for several weeks with oral dimercaptosuccinic acid, which apparently improved her clinical condition. ... 

There are also other immimological mechanisms, especially via IgG or IgM antibodies with immune complex formation, which can lead to similar clinical conditions [20, 34, 42] as has been shown in dextran anaphylaxis (table 1). Triggering of mast cells and basophils leads to release of various vasoactive mediators, among which histamine was the first recognized in 1908 (fig. 3,4) [6]. 

Knowledge of the biochemistry of the porphyrins and of heme is basic to understanding the varied functions of hemoproteins (see below) in the body. The porphyrias are a group of diseases caused by abnormalities in the pathway of biosynthesis of the various porphyrins. Although porphyrias are not very prevalent, physicians must be aware of them. A much more prevalent clinical condition is jaundice, due to elevation of bilirubin in the plasma. This elevation is due to overproduction of bilirubin or to failure of its excretion and is seen in numerous diseases ranging from hemolytic anemias to viral hepatitis and to cancer of the pancreas. 

In 1ST and CAST not all patients underwent brain imaging with CT before randomization. It was estimated that about 800 of the 40,000 included subjects in fact had ICH on subsequent imaging. The investigators found no indication in either trial that aspirin treatment led to a deterioration in clinical condition, leading the CAST group to suggest that the hazard of aspirin use in these patients cannot be large (Fig. 7.3). 

It has become clear that drugs which are effective in protecting mice against PTZ are effective in absence seizures while those able to control the tonic response to maximal electroshock are effective in tonic-clonic seizure. Some drugs are effective in only one test and clinical condition whilst a few are active in both (Table 16.1). Experimental focal seizures are indicative of partial seizures. 

Table 13.1 Some clinical conditions in which oxygen free radicals are thought to be involved ...

While the main goal of antihypertensive therapy is to achieve target blood pressures, the selection of agents for an individual should also account for certain special considerations and a patient s comorbidities. Specific antihypertensive therapy is warranted for certain patients with comorbid conditions that may elevate their level of risk for cardiovascular disease. Clinical conditions for which there is compelling evidence supporting one or more classes of drug therapy include 2... 

Drug Clinical Condition and ACC/AHA Guideline Recommendation Contraindications ... 

Because of the slow onset of CKD and the lack of symptoms in earlier stages, the prevalence of CKD is difficult to determine until patients reach ESRD. It is estimated that approximately 19 million people (11% of the United States population) have some degree of CKD.2 Approximately 8 million people have a GFR less than 60 mL/minute/1.73 m2,2 at which point CKD is generally diagnosed as a clinical condition. The prevalence of CKD is correlated with specific demographic factors increased age, African-American race, and hypertension. 

Clinical Condition First-Line Treatment Other Options... 

Bipolar disorders have been categorized into bipolar I disorder, bipolar II disorder, and bipolar disorder, not otherwise specified (NOS). Bipolar I disorder is characterized by one or more manic or mixed mood episodes. Bipolar II disorder is characterized by one or more major depressive episodes and at least one hypomanic episode. Hypomania is an abnormally and persistently elevated, expansive, or irritable mood, but not of sufficient severity to cause significant impairment in social or occupational function and does not require hospitalization. Most epidemiologic studies have looked at bipolar disorder of all types (bipolar I and bipolar II), or the bipolar spectrum, which includes all clinical conditions thought to be closely related to bipolar disorder. The lifetime prevalence of bipolar I disorder is estimated to be between 0.3% and 2.4%. The lifetime prevalence of bipolar II disorder ranges from 0.2% to 5%. When including the bipolar spectrum, the lifetime prevalence is between 3% and 6.5%.1... 

Other clinical conditions associated with insulin resistance (e.g., acanthosis nigricans)... 

---